Month: March 2020

DYNACOR REPORTS ITS 9TH CONSECUTIVE YEARLY PROFIT WITH A NET INCOME OF US$ 5.2 M IN 2019, AN 8% INCREASE

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

MONTREAL, March 30, 2020 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG / OTC: DNGDF) (Dynacor or the Corporation) has released its audited consolidated financial statements and the management’s discussion and analysis (MD&A) for the year ended December 31, 2019.These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com.(All figures in this press release are in millions of US$ unless stated otherwise. Earnings per share and cash-flow per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding).The financial results for 2019 reflect Dynacor’s ninth consecutive year of profits as the Corporation recorded a net income of $5.2 M ($0.13 or $0.17 CA per share), an increase...

Daré Bioscience Reports 2019 Financial Results and Provides a Company Update

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update.“During the fourth quarter of 2019 and into early 2020, we made considerable progress against our longer-term strategic and operational objectives, particularly with our later-stage candidates Ovaprene®, DARE-BV1, and Sildenafil Cream, 3.6%. This progress has helped position us for what we expect to be a transformative year for Daré. In 2020, we expect to achieve a number of important milestones that we believe will deliver value to our shareholders,” said Sabrina Martucci Johnson, President and CEO of Daré.“We started 2020 with the announcement of our exclusive licensing agreement with Bayer, a world leader in...

RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update on recent operational and business progress.“2019 was an especially productive year for RAPT with the completion of our initial public offering and the generation of encouraging early clinical data for our two lead immunology-based programs: FLX475 for the treatment of multiple cancers and RPT193 for the treatment of atopic dermatitis and other allergic inflammatory diseases,” said Brian Wong, M.D., Ph.D.,...

THE NEW AMERICA HIGH INCOME FUND, INC. DECLARES DIVIDEND, ANNOUNCES DIVIDEND CHANGE

Written by Customer Service on March 30, 2020. Posted in Dividend Reports And Estimates.

BOSTON, March 30, 2020 (GLOBE NEWSWIRE) — The New America High Income Fund, Inc. (the “Fund”) (NYSE: HYB) announced today that it will pay a dividend of $0.050 per share on the company’s common stock on April 30, 2020 to common shareholders of record as of the close of business on April 16, 2020 (the “April 2020 Dividend”). The ex-dividend date will be April 15th. The April 2020 Dividend represents a decrease of $0.005 from the Fund’s dividend of $0.055 that will be paid on March 31, 2020. In determining to reduce the dividend, the Board of Directors of the Fund considered information regarding the impact of the COVID-19 pandemic on, among other things, the Fund’s current and projected investment income from its holdings.The recent outbreak of COVID-19 has impacted issuers whose securities the Fund invests in and the market on which...

REPEAT – CHAMPIGNON EXPANDS PRECLINICAL PIPELINE WITH MEASURED PSILOCYBIN DOSAGES STUDIES AT UNIVERSITY OF MIAMI

Written by Customer Service on March 30, 2020. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 30, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of medicinal mushrooms health products and novel delivery platforms for the pharmaceutical and nutraceutical industries, has entered into a definitive agreement to acquire Tassili Life Sciences Corp. (“Tassili”), expanding the Company’s preclinical trial pipeline, as well as its aggregation of broad intellectual property (IP) related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases. Tassili, in partnership with a multidisciplinary team of scientists and physicians at the University of Miami are working to develop effective psilocybin-based...

RAPPEL – Champignon Brands élargit son portefeuille d’études précliniques grâce à des études mesurées de dosage de psilocybine à l’Université de Miami

Written by Customer Service on March 30, 2020. Posted in Mergers And Acquisitions.

VANCOUVER, Colombie-Britannique, 30 mars 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (« Champignon » ou la « société ») (CSE : SHRM) (FWB : 496) (OTC : SHRMF), une entreprise axée sur le bien-être et spécialisée dans la formulation d’une gamme de produits pour la santé à base de champignons médicinaux ainsi que dans les nouvelles plateformes de livraison pour les industries pharmaceutique et nutraceutique, a conclu une entente définitive pour faire l’acquisition de Tassili Life Sciences Corp. (« Tassili »), élargissant le pipeline d’essais précliniques de la société, ainsi que l’agrégation de propriété intellectuelle (« PI ») liée au développement de nouvelles thérapies psychédéliques ciblant de multiples maladies psychologiques pathologiques. Tassili collabore actuellement avec une équipe multidisciplinaire de scientifiques...

Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2019.“2019 was a tremendous year for Avenue. In February 2019, we closed the first stage of a two-stage equity investment and contingent acquisition transaction with InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of Cipla Limited,” said Lucy Lu, MD, Avenue’s President and Chief Executive Officer. “In June, we announced positive data from our second pivotal Phase 3 trial evaluating IV tramadol in patients following abdominoplasty surgery. The year culminated with the filing of a New Drug Application (“NDA”) with the FDA for IV tramadol in December,...

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend

Written by Customer Service on March 30, 2020. Posted in Dividend Reports And Estimates.

GREAT NECK, N.Y., March 30, 2020 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on February 7, 2020, a cash dividend of $0.11 per share will be paid to all shareholders of record on April 10, 2020. The dividend will be paid on April 15, 2020.

NTR Holding A/S: Indkaldelse til ordinær generalforsamling

Written by Customer Service on March 30, 2020. Posted in Public Companies.

Selskabsmeddelelse nr. 4 – 2020København, den 30. marts 2020Indkaldelse til ordinær generalforsamlingNTR Holding A/S afholder ordinær generalforsamling tirsdag den 21. april 2020, kl. 15.00, på adressen Axel Towers, Axeltorv 2, 1609 København V (Gorrissen Federspiel).Vigtig informationFor at minimere risikoen for smitte med COVID-19 og som følge af myndighedernes seneste anbefalinger og ændringer til epidemiloven anmodes vores aktionærer om at afholde sig fra at deltage personligt i den ordinære generalforsamling. Selskabet kan blive nødsaget til at aflyse den ordinære generalforsamling, hvis antallet af deltagere ikke er i overensstemmelse med gældende regler, jf. regeringens tiltag.Afgiv fuldmagtVi opfordrer alle vores aktionærer til at stemme ved afgivelse af fuldmagt til bestyrelsen i henhold til dens anbefalinger eller i henhold...

Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery

Written by Customer Service on March 30, 2020. Posted in Public Companies.

Company announcement – No. 10 / 2020Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgeryA subset of individuals who undergo gastric bypass bariatric surgery experience recurrent episodes of serious hypoglycemia after meals and no satisfactory treatments are available Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycemia after meals in individuals who have undergone bariatric surgery Development of a multi-dose pen is being pursued by Zealand Pharma to deliver adjustable mini-doses of dasiglucagon for treatment and prevention of recurrent episodes of hypoglycemia Copenhagen, March 30, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the...

Month: March 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals